Yusuke Muto

Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL

Kiyohiro Ando, Kazumasa Hiroishi, Takehisa Kaneko et al. · The Journal of Immunology · 1997 · 254 citations · Full text

Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study

Eiji Nakano, Akira Takahashi, Kenjiro Namikawa et al. · The Journal of Dermatology · 2020 · 56 citations

Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study

Kenjiro Namikawa, Akira Takahashi, Taisuke Mori et al. · Melanoma Research · 2019 · 40 citations

Single-institution Retrospective Study, Clinical Efficacy Outcomes, Translational Medicine +14

Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab

Yusuke Muto, Shigehisa Kitano, Arata Tsutsumida et al. · The Journal of Dermatology · 2019 · 26 citations

Advanced Melanoma Refractory, Medicine, Sequential Ipilimumab +13

Real‐world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma

Akira Takahashi, Kenjiro Namikawa, Dai Ogata et al. · The Journal of Dermatology · 2020 · 22 citations